AstraZeneca's Breast Cancer Drug Etcamah Misses Primary Goal in Phase III Trial
AstraZeneca's breast cancer drug Etcamah (camizestrant) failed to achieve a statistically significant improvement in progression-free survival in the Phase III SERENA-4 trial for advanced hormone receptor-positive, HER2-negative breast cancer. The trial combined Etcamah with palbociclib and compared it to standard treatment. Despite numerical improvement, the primary goal was unmet. The drug recently received accelerated FDA approval for a specific patient group based on separate SERENA-6 data. AstraZeneca continues to evaluate Etcamah in early breast cancer trials.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (44/100). Lens Score 44/100.
Outlets measured: economictimes, news18, ndtv. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (38–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
ndtv broke this story on 12 Sept, 09:39 am. Other outlets followed.